WHO announces LANDMARK changes in treatment of DR-TB

13 Jan 2023 • WHO has just released updated consolidated guidelines on the treatment of drug-resistant TB (DR-TB) featuring major improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB). The guidelines include a new recommendation on the use of a novel all-oral 6-month regimen composed of bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) in people suffering from MDR/RR-TB or MDR/RR-TB with additional resistance to fluoroquinolones (pre-XDR-TB). The newly recommended BPaLM regimen offers better outcomes, remarkably shortens the duration of treatment, and thus significantly improves quality of life for people with MDR/RR-TB. This is a historic change that will be of great benefit to people suffering from drug-resistant TB, easing the burden on health systems and saving lives,” said Dr. Tereza Kasaeva, Director of WHO’s Global TB Programme. “We now call for urgent action by national TB programmes and partners in rapidly transitioning to the new drug-resistant TB treatment regimen.’’

Source: WHO | Read full story

Contact us


+91 9023-729662

Medflix Logo

© 2022 Plexus Professionals Network Pvt Ltd